Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedJun 05, 2026
DataAggregated Company Financials
Companies20
  • 7D-2.9%
  • 3M10.9%
  • 1Y-35.0%
  • YTD-14.0%

Over the last 7 days, the Healthcare industry has dropped 5.9%, driven by Novo Nordisk declining 3.3%. The industry has fallen 37% in the last year. Looking forward, earnings are forecast to grow by 3.0% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 05 Jun 2026DKK 1.7tDKK 468.7bDKK 147.0b19.8x11.4x3.6x
Sun, 03 May 2026DKK 1.6tDKK 447.5bDKK 130.0b18.6x12.6x3.7x
Tue, 31 Mar 2026DKK 1.4tDKK 448.0bDKK 130.1b16.6x11x3.2x
Thu, 26 Feb 2026DKK 1.5tDKK 447.7bDKK 131.0b18.5x11.4x3.3x
Sat, 24 Jan 2026DKK 2.3tDKK 453.7bDKK 136.8b18.4x16.7x5x
Mon, 22 Dec 2025DKK 1.9tDKK 453.8bDKK 136.9b16.9x13.7x4.1x
Wed, 19 Nov 2025DKK 1.8tDKK 454.2bDKK 137.0b16.7x13.5x4.1x
Fri, 17 Oct 2025DKK 2.1tDKK 447.5bDKK 141.7b18.7x15.1x4.8x
Sun, 14 Sep 2025DKK 2.0tDKK 447.3bDKK 141.7b19.9x14.4x4.6x
Tue, 12 Aug 2025DKK 1.9tDKK 434.9bDKK 132.5b28.9x14.2x4.3x
Thu, 10 Jul 2025DKK 2.4tDKK 423.1bDKK 124.5b30x19.4x5.7x
Sat, 07 Jun 2025DKK 2.7tDKK 423.8bDKK 124.7b30.7x21.3x6.3x
Mon, 05 May 2025DKK 2.5tDKK 409.3bDKK 121.3b23x20.6x6.1x
Wed, 02 Apr 2025DKK 2.6tDKK 409.5bDKK 121.3b23.7x21.4x6.3x
Fri, 28 Feb 2025DKK 3.4tDKK 410.1bDKK 121.4b28.6x27.9x8.3x
Sun, 26 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b29.4x29.8x8.6x
Tue, 24 Dec 2024DKK 3.3tDKK 387.4bDKK 111.3b29.8x29.5x8.5x
Thu, 21 Nov 2024DKK 3.8tDKK 387.3bDKK 111.3b33.1x34.3x9.9x
Sat, 19 Oct 2024DKK 4.2tDKK 372.1bDKK 107.2b37.1x38.8x11.2x
Mon, 16 Sep 2024DKK 4.7tDKK 372.0bDKK 107.1b36x43.8x12.6x
Wed, 14 Aug 2024DKK 4.7tDKK 370.3bDKK 106.9b36.3x43.5x12.6x
Fri, 12 Jul 2024DKK 4.9tDKK 355.3bDKK 106.2b35.8x46x13.8x
Sun, 09 Jun 2024DKK 4.9tDKK 355.3bDKK 106.2b36.2x46.5x13.9x
Tue, 07 May 2024DKK 4.4tDKK 354.8bDKK 106.4b34.2x40.9x12.3x
Thu, 04 Apr 2024DKK 4.5tDKK 341.2bDKK 99.6b37.8x45.2x13.2x
Sat, 02 Mar 2024DKK 4.4tDKK 340.0bDKK 98.9b38x44.4x12.9x
Mon, 29 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b34.7x42x11.8x
Wed, 27 Dec 2023DKK 3.6tDKK 320.4bDKK 90.0b32.7x40.2x11.3x
Fri, 24 Nov 2023DKK 3.7tDKK 320.5bDKK 90.0b32.5x40.8x11.4x
Sun, 22 Oct 2023DKK 3.5tDKK 305.5bDKK 82.2b27.8x42.6x11.5x
Tue, 19 Sep 2023DKK 3.4tDKK 305.5bDKK 82.2b36.1x41.9x11.3x
Thu, 17 Aug 2023DKK 3.4tDKK 302.9bDKK 81.1b38.5x41.4x11.1x
Sat, 15 Jul 2023DKK 2.9tDKK 286.9bDKK 75.4b39x38.6x10.1x
Mon, 12 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40x39.9x10.5x
Price to Earnings Ratio

39.9x


Total Market Cap: DKK 3.0tTotal Earnings: DKK 75.5bTotal Revenue: DKK 287.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 30x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.0x which is lower than its 3-year average PE of 30.0x.
  • The 3-year average PS ratio of 8.6x is higher than the industry's current PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-1.03%
Healthcare-2.86%
Healthcare Services8.15%
Life Sciences4.35%
Healthtech0.22%
Medical Equipment-0.56%
Pharma-2.98%
Biotech-5.12%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 33.2x.
    • Analysts are expecting annual earnings growth of 20.2%, which is higher than its past year's earnings growth of 0.3% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 10% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DEMANT DemantDKK 252.203.6%
+DKK 1.9b		-1.0%PE22.5x
HLUN B H. LundbeckDKK 44.803.0%
+DKK 1.3b		21.1%PE11.9x
CHEMM ChemoMetecDKK 377.606.0%
+DKK 372.4m		-28.2%PE37.1x
EMBLA Embla Medical hfDKK 27.452.0%
+DKK 234.7m		-18.3%PE21.3x
ALK B ALK-AbellóDKK 266.200.4%
+DKK 221.6m		45.6%PE46.1x

Latest News

HLUN B
DKK 44.80
H. Lundbeck
7D
3.0%
1Y
21.1%
COLO B
DKK 383.70
Coloplast
7D
-3.5%
1Y
-39.0%
ZEAL
DKK 326.30
Zealand Pharma
7D
0.8%
1Y
-30.0%
AMBU B
DKK 66.00
Ambu
7D
0.6%
1Y
-33.6%
Narrative Update • Jun 03

AMBU B: Bearish Street Sentiment Will Support Future Upside Repricing

Analysts have reduced their price target on Ambu to DKK 88.8, citing a more cautious stance reflected in recent bearish Street research and downgrades. What's in the News Analysts have adopted a more cautious stance on Ambu, reflected in recent bearish research and rating downgrades from the Street.
NOVO B
DKK 283.85
Novo Nordisk
7D
-3.3%
1Y
-40.5%
BAVA
DKK 182.60
Bavarian Nordic
7D
-2.1%
1Y
1.2%
Narrative Update • Jun 01

BAVA: Public Preparedness Contracts And Vaccine Manufacturing Expansion Will Support 2026 Upside

Analysts have nudged their fair value estimate for Bavarian Nordic higher from DKK 268.33 to DKK 273.33. They point to adjusted assumptions around revenue growth, profit margins and future P/E as the main drivers of the updated price target.
GMAB
DKK 1,583.50
Genmab
7D
-6.8%
1Y
10.1%
ALK B
DKK 266.20
ALK-Abelló
7D
0.4%
1Y
45.6%
Narrative Update • May 29

ALK B: Future Upside Will Come From Allergy Immunotherapy Leadership

Analysts have lifted their price target on ALK-Abelló from DKK 263.33 to DKK 297.50, citing the company’s position as a global leader in allergy immunotherapy and recent supportive research coverage. Analyst Commentary Analysts setting a DKK 305 price target frame ALK-Abelló as a global leader in allergy immunotherapy, and they use that positioning to support a constructive view on the stock’s long term potential.
GUBRA
DKK 355.20
Gubra
7D
2.5%
1Y
-23.0%
Narrative Update • May 26

GUBRA: Obesity Pipeline Progress And Phase 2 Milestones Will Drive Long Term Upside

Analysts have trimmed their price target for Gubra from DKK 469.50 to DKK 451.50, citing slightly softer revenue growth expectations and a modestly lower projected profit margin. This is partly offset by a small reduction in the discount rate and a marginally lower future P/E assumption.
DEMANT
DKK 252.20
Demant
7D
3.6%
1Y
-1.0%
BIOPOR
DKK 1.30
BioPorto
7D
-3.7%
1Y
-4.9%
EMBLA
DKK 27.45
Embla Medical hf
7D
2.0%
1Y
-18.3%
Narrative Update • May 19

EMBLA: Share Cancellations And Renewed Capital Authorisations Will Support Future Upside

Analysts have kept their DKK price target for Embla Medical hf. broadly steady at DKK 33.3, reflecting only minor tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions in their updated models.
CHEMM
DKK 377.60
ChemoMetec
7D
6.0%
1Y
-28.2%
STENO
DKK 1.06
Stenocare
7D
-6.6%
1Y
141.5%
PEG
DKK 0.068
Pharma Equity Group
7D
-7.6%
1Y
-36.9%
STRAP
DKK 580.00
Strategic Partners
7D
-2.5%
1Y
-42.9%